Abstract
Mature results from GOG158 have clearly established carboplatin and paclitaxel as an effective and well-tolerated standard regimen, providing a basis for the reference arm in GOG0182-ICON5, an ongoing multiarmed phase III trial of the Gynecologic Cancer InterGroup (GCIG) evaluating the incorporation of newer cytotoxic agents. Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carboplatin / administration & dosage
-
Cisplatin / administration & dosage
-
Clinical Trials, Phase III as Topic
-
Female
-
Humans
-
Neoplasm Metastasis
-
Neoplasm Staging
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / mortality*
-
Ovarian Neoplasms / pathology
-
Ovarian Neoplasms / surgery
-
Paclitaxel / administration & dosage
-
Second-Look Surgery
-
Survival Analysis
Substances
-
Carboplatin
-
Paclitaxel
-
Cisplatin